Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell
Culture Technology-Based Vaccines to Revolutionize the Market by Faster
Production and High Initial Purity
Summary
GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.
Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.
GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.
GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.
GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.
Scope
- Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
- Market forecasts for the seasonal influenza vaccines from 2010 to 2017
- Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
- Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.
Reasons to buy
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11
2 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Introduction 14
2.1 GBI Research Report Guidance 15
3 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Market Overview 16
3.1 Production Cycle for the Seasonal Influenza Vaccines 16
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market 16
3.3 Revenue for the Seasonal Influenza Vaccine Market 17
3.4 Geographical Segmentation 19
4 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Geographical Landscape 20
4.1 Australia 20
4.1.1 Vaccination Pattern 20
4.1.2 Cost of Vaccine 25
4.1.3 Total Revenue 26
4.2 New Zealand 28
4.2.1 Vaccination Pattern 28
4.2.2 Cost of Vaccine 33
4.2.3 Total Revenue 34
4.2.4 Major Players by Market Share 36
4.3 Taiwan 37
4.3.1 Vaccination Pattern 37
4.3.2 Cost of Vaccine 41
4.3.3 Total Revenue 42
4.3.4 Major Players by Market Share 44
4.4 Philippines 45
4.4.1 Vaccination Pattern 45
4.4.2 Cost of Vaccine 49
4.4.3 Total Revenue 50
4.4.4 Major Players by Market Share 52
4.5 Malaysia 53
4.5.1 Vaccination Pattern 53
4.5.2 Cost of Vaccine 57
4.5.3 Total Revenue 58
4.5.4 Major Players by Market Share 60
4.6 Hong Kong 61
4.6.1 Vaccination Pattern 61
4.6.2 Cost of Vaccine 65
4.6.3 Total Revenue 66
4.6.4 Major Players by Market Share 68
4.7 Singapore 69
4.7.1 Vaccination Pattern 69
4.7.2 Cost of Vaccine 73
4.7.3 Total Revenue 74
4.7.4 Major Players by Market Share 76
4.8 Japan 77
4.8.1 Vaccination Pattern 77
4.8.2 Cost of Vaccine 81
4.8.3 Total Revenue 82
4.8.4 Major Players in the Market 83
4.9 China 84
4.9.1 Vaccination Pattern 84
4.9.2 Cost of Vaccine 88
4.9.3 Total Revenue 89
4.9.4 Major Players in the Market 91
4.10 India 92
4.10.1 Vaccination Pattern 92
4.10.2 Cost of Vaccine 96
4.10.3 Total Revenue 97
4.10.4 Major Players in the Market 99
5 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Drivers and Restraints 100
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 100
5.1.1 Threat of Pandemic Influenza 100
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines 101
5.1.3 Emergence of Novel Production Technologies and Vaccines 104
5.1.4 Population Growth 105
5.1.5 Economic Reasons 105
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 105
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market 105
5.2.2 Variable Demand 106
5.2.3 Limited Production Capacity 106
5.3 Australia 106
5.3.1 Drivers 106
5.3.2 Restraints 106
5.4 New Zealand 107
5.4.1 Drivers 107
5.4.2 Restraints 107
5.5 Taiwan 107
5.5.1 Drivers 107
5.5.2 Restraints 107
5.6 Philippines 108
5.6.1 Drivers 108
5.6.2 Restraints 108
5.7 Malaysia 108
5.7.1 Drivers 108
5.7.2 Restraints 108
5.8 Hong Kong 109
5.8.1 Drivers 109
5.8.2 Restraints 109
5.9 Singapore 109
5.9.1 Drivers 109
5.9.2 Restraints 110
5.10 Japan 110
5.10.1 Drivers 110
5.10.2 Restraints 110
5.11 China 111
5.11.1 Drivers 111
5.11.2 Restraints 111
5.12 India 111
5.12.1 Drivers 111
5.12.2 Restraints 111
6 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Regulatory Landscape 112
6.1 Registration Process and Regulations in Australia 112
6.2 Registration Process and Regulations in New Zealand 114
6.3 Registration Process and Regulations in Taiwan 117
6.4 Registration Process and Regulations in the Philippines 118
6.5 Registration Process and Regulations in Malaysia 120
6.6 Registration Process and Regulations in Hong Kong 122
6.7 Registration Process and Regulations in Singapore 123
6.8 Registration Process and Regulations in Japan 124
6.9 Registration Process and Regulations in China 126
6.10 Registration Process and Regulations in India 128
7 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Pipeline Analysis 130
7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development 130
7.2 Profiles for Promising Vaccines under Clinical Development 131
7.2.1 Optaflu 131
7.2.2 GSK2186877A 131
7.2.3 Intanza / Flu-ID 132
7.2.4 Fluad Pediatric 133
7.2.5 FluBlok 133
7.3 Research and Development Pipeline 134
8 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Competitive Landscape 138
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region 138
8.1.1 Fluarix 138
8.1.2 Vaxigrip 138
8.1.3 Influvac 138
8.1.4 Fluvax 138
8.1.5 Agrippal 138
8.2 Key Areas Focused for R&D 139
8.3 Competitive Profiling 140
8.3.1 Sanofi Pasteur 140
8.3.2 GlaxoSmithKline Biologicals 140
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals) 140
8.3.4 CSL Biotherapies 140
8.3.5 Novartis Vaccines 141
8.3.6 Crucell N.V. (Berna Biotech) 141
9 Seasonal Influenza Vaccine Market in Asia-Pacific Region – M&A Landscape 142
9.1 Overview 142
9.2 Major Merger and Acquisition Deals, 2007-2011 142
9.2.1 AstraZeneca Acquires Medimmune 143
9.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis 143
9.2.3 Mymetics Acquires Virosome Biologicals 143
9.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 143
9.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan 144
9.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 144
9.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 144
9.2.8 Johnson & Johnson Acquires Crucell 144
9.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals 144
9.3 M&A Deals by Year of Completion, 2007-2011 145
9.4 M&A Deals by Geography 146
9.5 Major Licensing Agreements, 2007-2011 146
9.5.1 Crucell enters into License Agreement with Adimmune Corporation 146
9.5.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur 147
9.5.3 Vivalis enters into Licensing Agreement with GlaxoSmithKline 147
9.5.4 Vivalis enters into Licensing Agreement with Nobilon International 147
9.5.5 MedImmune enters into Licensing Agreement with GlaxoSmithKline 147
9.5.6 Hemispherx Biopharma Enters Into Licensing Agreement with BIKEN 147
9.5.7 MedImmune Enters Into Licensing Agreement with BIKEN 147
9.5.8 MedImmune Enters Into Licensing Agreement with Omninvest 148
9.5.9 OPKO Health Enters Into Licensing Agreement with Academia Sinica 148
9.5.10 AltraVax Enters Into Licensing Agreement with Maxygen 148
9.5.11 Protein Sciences Expands Its Licensing Agreement with UMN Pharma for FluBlok and PanBlok 148
9.5.12 NasVax Extends Its Research Agreement with Novartis 148
9.5.13 iBio Enters Into Licensing Agreement With G-Con 148
9.6 Licensing Deals by Year of Completion, 2007-2011 149
9.7 Licensing Deals by Geography 150
10 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Appendix 151
10.1 Market Definitions 151
10.2 Abbreviations 151
10.3 Research Methodology 152
10.3.1 Coverage 152
10.3.2 The Scope of the Study 152
10.3.3 Secondary Research 153
10.3.4 Primary Research 153
10.3.5 Expert Panel Validation 155
10.4 Contact Us 156
10.5 Disclaimer 156
10.6 Sources 156
Summary
GBI Research, the leading business intelligence provider has released its latest research “Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity Description” which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2017. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.
Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.
GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 8.9% during the period 2010-2017 from $1,154.9m in 2010 to $2,095.9m by 2017. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments’ support, growing population in the APAC region and entry of novel vaccines and production technologies.
GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2010-2017. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.
GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.
Scope
- Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
- Market forecasts for the seasonal influenza vaccines from 2010 to 2017
- Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
- Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.
Reasons to buy
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 11
2 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Introduction 14
2.1 GBI Research Report Guidance 15
3 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Market Overview 16
3.1 Production Cycle for the Seasonal Influenza Vaccines 16
3.2 The Asia-Pacific Region Seasonal Influenza Vaccine Market 16
3.3 Revenue for the Seasonal Influenza Vaccine Market 17
3.4 Geographical Segmentation 19
4 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Geographical Landscape 20
4.1 Australia 20
4.1.1 Vaccination Pattern 20
4.1.2 Cost of Vaccine 25
4.1.3 Total Revenue 26
4.2 New Zealand 28
4.2.1 Vaccination Pattern 28
4.2.2 Cost of Vaccine 33
4.2.3 Total Revenue 34
4.2.4 Major Players by Market Share 36
4.3 Taiwan 37
4.3.1 Vaccination Pattern 37
4.3.2 Cost of Vaccine 41
4.3.3 Total Revenue 42
4.3.4 Major Players by Market Share 44
4.4 Philippines 45
4.4.1 Vaccination Pattern 45
4.4.2 Cost of Vaccine 49
4.4.3 Total Revenue 50
4.4.4 Major Players by Market Share 52
4.5 Malaysia 53
4.5.1 Vaccination Pattern 53
4.5.2 Cost of Vaccine 57
4.5.3 Total Revenue 58
4.5.4 Major Players by Market Share 60
4.6 Hong Kong 61
4.6.1 Vaccination Pattern 61
4.6.2 Cost of Vaccine 65
4.6.3 Total Revenue 66
4.6.4 Major Players by Market Share 68
4.7 Singapore 69
4.7.1 Vaccination Pattern 69
4.7.2 Cost of Vaccine 73
4.7.3 Total Revenue 74
4.7.4 Major Players by Market Share 76
4.8 Japan 77
4.8.1 Vaccination Pattern 77
4.8.2 Cost of Vaccine 81
4.8.3 Total Revenue 82
4.8.4 Major Players in the Market 83
4.9 China 84
4.9.1 Vaccination Pattern 84
4.9.2 Cost of Vaccine 88
4.9.3 Total Revenue 89
4.9.4 Major Players in the Market 91
4.10 India 92
4.10.1 Vaccination Pattern 92
4.10.2 Cost of Vaccine 96
4.10.3 Total Revenue 97
4.10.4 Major Players in the Market 99
5 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Drivers and Restraints 100
5.1 Drivers for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 100
5.1.1 Threat of Pandemic Influenza 100
5.1.2 Increasing Vaccination Coverage for Seasonal Influenza Vaccines 101
5.1.3 Emergence of Novel Production Technologies and Vaccines 104
5.1.4 Population Growth 105
5.1.5 Economic Reasons 105
5.2 Restraints for the Seasonal Influenza Vaccine Market in the Asia-Pacific Region 105
5.2.1 Entry Barriers in the Seasonal Influenza Vaccine Market 105
5.2.2 Variable Demand 106
5.2.3 Limited Production Capacity 106
5.3 Australia 106
5.3.1 Drivers 106
5.3.2 Restraints 106
5.4 New Zealand 107
5.4.1 Drivers 107
5.4.2 Restraints 107
5.5 Taiwan 107
5.5.1 Drivers 107
5.5.2 Restraints 107
5.6 Philippines 108
5.6.1 Drivers 108
5.6.2 Restraints 108
5.7 Malaysia 108
5.7.1 Drivers 108
5.7.2 Restraints 108
5.8 Hong Kong 109
5.8.1 Drivers 109
5.8.2 Restraints 109
5.9 Singapore 109
5.9.1 Drivers 109
5.9.2 Restraints 110
5.10 Japan 110
5.10.1 Drivers 110
5.10.2 Restraints 110
5.11 China 111
5.11.1 Drivers 111
5.11.2 Restraints 111
5.12 India 111
5.12.1 Drivers 111
5.12.2 Restraints 111
6 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Regulatory Landscape 112
6.1 Registration Process and Regulations in Australia 112
6.2 Registration Process and Regulations in New Zealand 114
6.3 Registration Process and Regulations in Taiwan 117
6.4 Registration Process and Regulations in the Philippines 118
6.5 Registration Process and Regulations in Malaysia 120
6.6 Registration Process and Regulations in Hong Kong 122
6.7 Registration Process and Regulations in Singapore 123
6.8 Registration Process and Regulations in Japan 124
6.9 Registration Process and Regulations in China 126
6.10 Registration Process and Regulations in India 128
7 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Pipeline Analysis 130
7.1 Seasonal Influenza Vaccines – Promising Vaccines under Clinical Development 130
7.2 Profiles for Promising Vaccines under Clinical Development 131
7.2.1 Optaflu 131
7.2.2 GSK2186877A 131
7.2.3 Intanza / Flu-ID 132
7.2.4 Fluad Pediatric 133
7.2.5 FluBlok 133
7.3 Research and Development Pipeline 134
8 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Competitive Landscape 138
8.1 Major Seasonal Influenza Vaccines Marketed in the APAC Region 138
8.1.1 Fluarix 138
8.1.2 Vaxigrip 138
8.1.3 Influvac 138
8.1.4 Fluvax 138
8.1.5 Agrippal 138
8.2 Key Areas Focused for R&D 139
8.3 Competitive Profiling 140
8.3.1 Sanofi Pasteur 140
8.3.2 GlaxoSmithKline Biologicals 140
8.3.3 Abbott Laboratories (Solvay Pharmaceuticals) 140
8.3.4 CSL Biotherapies 140
8.3.5 Novartis Vaccines 141
8.3.6 Crucell N.V. (Berna Biotech) 141
9 Seasonal Influenza Vaccine Market in Asia-Pacific Region – M&A Landscape 142
9.1 Overview 142
9.2 Major Merger and Acquisition Deals, 2007-2011 142
9.2.1 AstraZeneca Acquires Medimmune 143
9.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis 143
9.2.3 Mymetics Acquires Virosome Biologicals 143
9.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 143
9.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan 144
9.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 144
9.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 144
9.2.8 Johnson & Johnson Acquires Crucell 144
9.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals 144
9.3 M&A Deals by Year of Completion, 2007-2011 145
9.4 M&A Deals by Geography 146
9.5 Major Licensing Agreements, 2007-2011 146
9.5.1 Crucell enters into License Agreement with Adimmune Corporation 146
9.5.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur 147
9.5.3 Vivalis enters into Licensing Agreement with GlaxoSmithKline 147
9.5.4 Vivalis enters into Licensing Agreement with Nobilon International 147
9.5.5 MedImmune enters into Licensing Agreement with GlaxoSmithKline 147
9.5.6 Hemispherx Biopharma Enters Into Licensing Agreement with BIKEN 147
9.5.7 MedImmune Enters Into Licensing Agreement with BIKEN 147
9.5.8 MedImmune Enters Into Licensing Agreement with Omninvest 148
9.5.9 OPKO Health Enters Into Licensing Agreement with Academia Sinica 148
9.5.10 AltraVax Enters Into Licensing Agreement with Maxygen 148
9.5.11 Protein Sciences Expands Its Licensing Agreement with UMN Pharma for FluBlok and PanBlok 148
9.5.12 NasVax Extends Its Research Agreement with Novartis 148
9.5.13 iBio Enters Into Licensing Agreement With G-Con 148
9.6 Licensing Deals by Year of Completion, 2007-2011 149
9.7 Licensing Deals by Geography 150
10 Seasonal Influenza Vaccine Market in Asia-Pacific Region – Appendix 151
10.1 Market Definitions 151
10.2 Abbreviations 151
10.3 Research Methodology 152
10.3.1 Coverage 152
10.3.2 The Scope of the Study 152
10.3.3 Secondary Research 153
10.3.4 Primary Research 153
10.3.5 Expert Panel Validation 155
10.4 Contact Us 156
10.5 Disclaimer 156
10.6 Sources 156
